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Abstract Isolation of the pulmonary veins may be an effec-
tive treatment modality for eliminating atrial fibrillation (AF)
episodes but unfortunately not for all patients. When ablative
therapy fails, it is assumed that AF has progressed from a
trigger-driven to a substrate-mediated arrhythmia. The effect
of radiofrequency ablation on persistent AF can be attributed
to various mechanisms, including elimination of the trigger,
modification of the arrhythmogenic substrate, interruption of
crucial pathways of conduction, atrial debulking, or atrial
denervation. This review discusses the possible effects of
pulmonary vein isolation on the fibrillatory process and the
necessity of cardiac mapping in order to comprehend the
mechanisms of AF in the individual patient and to select the
optimal treatment modality.
Keywords Atrial fibrillation . Pulmonary vein isolation .
Cardiac surgery . Cardiacmapping
Atrial fibrillation (AF) is at this moment a major subject of
interest for both clinicians and scientists. The interest for AF is
partly the result of the fact that AF is the most common
arrhythmia and therefore frequently encountered in daily clin-
ical practice. As it is more common in the elderly (5 % in
subjects >60 years), the incidence of AF will only continue to
rise due to ageing of the population. Subjects with AF repre-
sent a spectrum of patients with arrhythmia episodes varying
in duration, number, pattern of onset, triggers and mode of
termination. In addition, the arrhythmia presentation itself can
also change over time. Despite the variable clinical presenta-
tion, AF is characterised by an irregular heartbeat, stasis of
blood flow in the left atrial appendage which increases the
vulnerability to thromboembolism, and loss of the atrial kick
that may compromise cardiac haemodynamics. Hence, these
severe sequelae of AF require effective treatment [1–4].
In 1998, Haïssaguere et al. demonstrated that paroxysms of
AF can be triggered by ectopic foci mainly located within the
pulmonary veins (PV) [5]. Electrical isolation of the pulmo-
nary veins (PVI) has since then been regarded as a potentially
curative therapy and is nowadays indicated as a class Ia
treatment modality for patients with symptomatic paroxysmal
AF in whom antiarrhythmic drug therapy has failed [6].
Examples of various ablation technologies are demonstrated
in Fig. 1. Numerous studies have provided evidence that PVI
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can be an effective treatment modality, but unfortunately not
for all patients [7–9]. Miyazaki et al. studied AF recurrences
after PVI in 574 patients (paroxysmal AF: 452, persistent AF:
122). Twenty-seven months after the first PVI, 376 patients
maintained sinus rhythm without the aid of antiarrhythmic
drugs (paroxysmal AF: 304, persistent AF: 72). The other
patients needed multiple (maximum of 4) redo procedures.
Early recurrences of AF after 6 months revealed that they were
mainly due to recovered PV conduction, whereas recurrences
after 1 year were mainly caused by non-pulmonary vein
triggers [7]. Kottkamp et al. reported the long-term outcome
of ablative therapy in 80 patients with paroxysmal AF and 20
patients with persistent AF. Seven-day Holter recordings were
taken before ablation, within 1 h after ablation and 3, 6 and
12 months after ablation. In patients with paroxysmal AF, AF
episodes decreased over time (74 %). In patients with persis-
tent AF and recurrences after ablation, the number of AF
episodes increased over time but the duration of these AF
episodes diminished. After a follow-up period of 12 months,
only 22 % of the patients with longstanding persistent AF
(LsPAF) were free of AF episodes. From these findings the
authors suggested that PV trigger elimination did not play a
role in abolishing LsPAF and that ablation might only have
modified the arrhythmogenic substrate [10].
Several studies were conducted to examine whether PVI
was actually more effective than antiarrhythmic drug therapy
in eliminating AF episodes. The Medical ANtiarrhythmic
Treatment or Radiofrequency Ablation in Paroxysmal Atrial
Fibrillation (MANTRA-AF) trial was the first large
randomised multicentre trial, comparing the efficacy of PVI
versus antiarrhythmic drug therapy. Altogether, 294 patients
were enrolled over a period of 3 years; 148 patients were
treated with antiarrhythmic drug therapy and 146 underwent
pulmonary vein isolation. In order to assess the AF burden,
continuous rhythm monitoring was performed for 7 days at
baseline, and 3, 6, 12, 18 and 24 months after initiation of
therapy. A significant difference in AF burden was found
between the PVI and AAD group at 24-month follow-up
(9 % vs. 18 %, respectively; p =0.007). However, the cumu-
lative AF burden during the entire follow-up period revealed
no significant difference between the two groups (13 % and
19 %, respectively; p =0.10) [11].
Effects of the pulmonary vein isolation procedure
Why and when is PVI a successful procedure for AF? The
success of PVI in eliminating AF episodes can be attributed to
a number of factors such as: 1) isolation of the trigger(s), 2)
modification of the arrhythmogenic substrate located in the
left atrial posterior wall, 3) interruption of crucial pathways of
conduction, 4) atrial debulking or 5) atrial denervation.
It is generally assumed that the arrhythmogenic substrate




















Fig. 1 Pulmonary vein isolation technologies. Isolation of the pulmonary
veins using cryothermal energy (panel a) or radiofrequency energy (panel
b). Panel a : A cryothermal balloon catheter (red arrow) is positioned into
the left superior pulmonary vein and circumferential ostial ablation results
in the disappearance of PV potentials (P). Panel b : An endovascular,
remote, steerable, radiofrequency ablation catheter is positioned in the left
superior pulmonary vein. The radiofrequency ablation catheter in a steer-
able sheath is attached to a robotic arm (red arrow), which is controlled
from a workstation (W). The workstation is equipped with an instinctive
motion controller (IMC) which provides tactile feedback. Navigation with
the robotic arm is facilitated by a three-dimensional electroanatomical map
of the left atrium (LA)
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‘rapid electrical activity’ (organised electrograms with rela-
tively short cycle lengths) during AF was found at the left
atrial posterior wall. Recently, Shivkumar et al. tested the
feasibility of Focal Impulse and Rotor Modulation (FIRM)
by a novel method in 12 patients (paroxysmal AF: 1; persis-
tent AF: 11) in a multicentre setting [12]. Unipolar AF elec-
trograms were obtained by a 64-pole basket catheter (IE
4–8 mm). In these patients, they identified 18 locations of
‘rapid electric activity’ in the left atrium and 5 in the right
atrium; 21 were labelled as rotors. The procedural endpoint
was defined as acute AF termination or organisation
(>10 % cycle length prolongation) and was conceived in all
patients. FIRM demonstrated localised AF rotors/focal
sources in patients with different AF types and recommended
larger studies with follow-up and randomisation. Consequent-
ly, they initiated the Conventional ablation for atrial fibrilla-
tion with or without Focal Impulse and Rotor Modulation
(CONFIRM) trial containing 92 patients (paroxysmal AF:
26; persistent AF: 66) undergoing 107 consecutive ablation
procedures [13]. They allocated patients to FIRM following
conventional ablation (N =36; PAF: 7; persistent AF: 29) or
conventional ablation alone (N =71). In 97 % of the proce-
dures, they observed focal activity (left atrium 76 %; right
atrium 24 %). Acute success was achieved in 86 % of FIRM
versus 20 % of conventional ablation. In addition, patients
with FIRM had a higher freedom of AF episodes (82.4 % vs.
44.9 %; p >0.001) during an averaged follow-up period of
273 days. Hence, it was claimed that FIRM-guided ablation
might be a more efficient AF ablation approach for both
paroxysmal and persistent AF.
Alterations in refractoriness may also contribute to PV
arrhythmogenicity. Jais et al. assessed both the effective and
functional refractory period in patients with and without a
history of AF [14]. In patients with AF, the refractory period
in the PV area was shorter than in the left atrium. On the
contrary, in the control group the refractory period in the left
atrium was shorter than in the PVarea. Comparing the control
and the AF group, the refractory period in the PV was signif-
icantly shorter in the AF patients. Hence, the relatively shorter
refractory period of the PV area seems to contribute to its
arrhythmogenicity. Haissaguerre et al. observed that AF cycle
length within the coronary sinus progressively increased dur-
ing PVI [15]. Based on their observations and data from other
studies demonstrating reentry in the PV-left atrial junction
region they stated that in some patients with AF, the PV-left
atrial junction region is a generator of venouswavesmaintaining
AF (the ‘venous wave hypothesis’) [16].
Disconnection of crucial intra-atrial conduction pathways,
e.g. the Marshall bundle, located at the PV-left atrium junc-
tion, may also explain why PVI is successful in eliminating
AF. The Marshall bundle is located within the vein of Mar-
shall close to the left superior PV and connects the coronary
sinus muscle sleeve to the left atrium. Epicardial mapping
studies in canine atria demonstrated that the Marshall bundle
may serve as a source of atrial ectopy giving rise to AF. Direct
connections between the Marshall bundle and the left
superior PV contributed to focal activity within the left
superior PV. When conduction between the PV and left
atrium was slowed by ablation, focal activation within
the left superior PV was prevented, despite persistent
focal activation originating from the Marshall bundle in
some dogs. This finding also suggests that the Marshall bundle
can be regarded as an accessory pathway to the left superior PV
and may explain why circular lesions fail to isolate the PV.
However, evidence from human data supporting this hypothe-
sis is lacking [17].
Another hypothesis for the success of the PVI is atrial
debulking. ‘The critical mass of fibrillation’ hypothesis states
that a certain minimal size of atrial tissue is essential for
initiation and sustenance of AF [18, 19]. Perpetuation of AF
is determined by the number of simultaneously wandering
wavelets [20]. Thus, a larger atrial mass can accommodate
more wavelets, thereby stabilising AF and reduction of atrial
mass may therefore be anti-fibrillatory. It is thought that PVI
diminishes atrial mass as a significant amount of atrial myo-
cardium may be replaced by scar tissue [18, 19].
Finally, effectiveness of the PVI can also be explained by
atrial denervation. There is accumulating evidence that the
autonomic nervous system plays a role in the pathogenesis of
AF. Vagal stimulation increases spatial dispersion in atrial
refractoriness, caused by e.g. local variability in density of
vagal nerve endings/muscarine receptors, discrepancies in the
coupling of muscarine receptors to ion-channel effectors, var-
iation in K+-channel density or variations in the distribution of
acetylcholinesterase. A higher vagal tone due reduced acetyl-
cholinesterase activity has indeed been demonstrated in pa-
tients with AF [21]. Pappone et al. analysed heart rhythm
variability and found a post-ablation shift of the sympathovagal
balance towards parasympathetic predominance. In a subse-
quent study, vagal denervation was performed in 297 patients
with paroxysmal AF referred for PVI. Vagal sites were defined
as sites where vagal reflexes (bradycardia, asystole, atrioventric-
ular block, hypotension) occurred during ablation. At such a site,
ablation was performed until the vagal reflexes were completely
abolished. Vagal reflexes were present in 104 patients; ablation
sites were located at the cranial left superior PV-left atrium, the
septal right superior PV-left atrium, the posteroinferior left infe-
rior PV-left atrium and the posteroinferior right inferior PV-left
atrium junction. In patients who have had a vagal denervation,
late recurrences were less frequently observed though
there was a higher incidence of early recurrences compared
with patients without vagal denervation. This finding was
explained by destruction of vagal nerve fibres resulting in
release of acetylcholine causing early recurrences, followed
by a stable vagolytic effect later after ablationwhich prevented
AF recurrences [22].
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Fig. 2 Principles of isochronal
mapping. Upper panel : unipolar
epicardial atrial electrogram
recorded during sinus rhythm.
Lower panel : unipolar epicardial
atrial potentials recorded at every
electrode (N =60) within a
mapping area of 1.10 cm2. Red
lines indicate the local activation
time at every electrode. A colour-
coded activation map with
isochrones (black lines) drawn at
10 ms shows that the wavefront is
propagating from the lower right
corner towards the upper left





Fig. 3 Unipolar electrograms
during induced and long-standing
persistent atrial fibrillation.
Unipolar, epicardial atrial
electrograms recorded from the
middle of the right atrial free wall
during induced AF (upper panel)
and long-standing persistent
AF (lower panel). Recordings
obtained from the patient with
long-standing persistent AF are
more complex, containing
fractionated potentials
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So why and when may PVI then NOT be effective in
eliminating AF? It is assumed that in patients with long-
standing persistent atrial fibrillation, AF has progressed from
a trigger-driven to a substrate-mediated arrhythmia. In these
patients, persistence of AF no longer depends on the presence
of a trigger but is maintained by an ‘arrhythmogenic substrate’
(‘true fibrillation’). Patients presenting with AF may have
underlying structural heart diseases affecting atrial architec-
ture and/or electrical function thereby creating a substrate
capable of perpetuating AF. In addition to this, AF itself
may also modify the atrial myocardium which in turn
stabilises AF. For example, AF results in shortening of the
atrial effective refractory period and reversion of the physio-
logical rate adaptation (shortening of the atrial refractory
period at slower heart rates), facilitating inducibility and sta-
bility of AF (electrical remodelling) [23]. Longstanding AF in
the goat model of AF is associated with changes in myocardial
structure including dedifferentation, increase in cell size,
perinuclear accumulation of glycogen, central loss of sarco-
meres, changes in mitochondrial shape, fragmentation of the
sarcoplasmatic reticulum and disorganisation of fibre orienta-
tion (structural remodelling) [24]. Unfortunately, data on his-
topathological alterations in humans with AF are limited [25].
There are numerous electrophysiological, structural and
neurohormonal alterations creating a vulnerable substrate for
AF. As it is likely that electrical and/or structural remodelling
affects multiple sites of the atria, the arrhythmogenic substrate
of AF will not only be confined to the PV area. This hypoth-
esis is supported by the outcome of the IRAAF study (The
Intraoperative Radiofrequency Ablation of Atrial Fibrillation)
[26]. In this study, creation of linear lesions in the left atrium
without PVI eliminated AF in more than 90 % of the patients.
Ablation of AF should either destroy the trigger mechanism or
alter the substrate perpetuating AF. However, a selective ab-
lation approach requires knowledge of the mechanisms un-
derlying AF in the individual patient. Cardiac mapping may
be a suitable tool to acquire knowledge of the arrhythmogenic
substrate necessary for selection of the optimal ablation
strategy.
Cardiac mapping
Cardiac mapping was originally defined as a method bywhich
potentials recorded directly from the surface of the heart are
spatially depicted as a function of time in an integratedmanner
0 50 100 ms 
Fig. 4 Activation maps during permanent atrial fibrillation. Eighteen
consecutive colour-coded activation maps of the right atrium (area
1.10 cm2) obtained from a patient with mitral valve disease. The maps
show clear beat-to-beat changes in the pattern of activation. The earliest to
latest activated areas are coloured from red to dark purple
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[27]. The most commonly used cardiac mapping approach is
isochronal or activation mapping, which is aimed at creating a
spatial model of the excitation sequence. Extracellular poten-
tial features are used to detect the local activation time of
myocardium surrounding the recording electrode. Isochronal
mapping during sinus rhythm is demonstrated in Fig. 2. A
template containing 60 unipolar electrodes records extracellu-
lar potentials from a 1.10 cm2 area of epicardial atrial tissue at
the right atrial free wall. An example of an unipolar atrial
electrogram recorded during sinus rhythm, containing a local
atrial potential (A) and a far-field ventricular potential (V), is
shown at the top. Each potential in the electrogram has an
identical morphology. The local activation time is determined
by marking the maximum negative slope (red lines). This
information is used to construct a colour-coded activation
map. The moment that the wavefront enters the mapping area
is defined as 0 ms. Isochrones are lines connecting simulta-
neously activated recording sites and are drawn at 10-ms
intervals. The propagation direction of the wavefront is per-
pendicular to the isochrones and indicated by a black arrow.
The resulting activation maps show a wavefront propagating
from the lower right corner towards the upper left corner
within 20 ms.
As demonstrated by this example, the main element in
cardiac mapping is thus correct interpretation of the morphol-
ogy of extracellular potentials. Figure 3 shows a collection of
40 30 30 40 ms 
EPI 
ENDO 
0 10 20 30 ms 
25 
139 EB 
Fig. 5 Electropathological substrate of atrial fibrillation: longitudinal
dissociation and epicardial breakthrough. Left panel: example of a wave
map of the right atrial free wall of a patient with long-standing persistent
AF and mitral valve disease. This wave map was reconstructed using an
algorithm separating fibrillation waves with an interelectrode conduction
time of ≥12 ms everywhere along their boundaries. The sequence of
appearance of the waves is indicated by the rainbow colour scheme.
Arrows indicate the main trajectories of the different fibrillation waves.
These maps show two types of fibrillation wave: peripheral waves,
entering the mapping area from outside the electrode array (black arrows)
and epicardial breakthrough waves, appearing at the epicardial surface
inside the mapping area (white arrows). Lower left panel : corresponding
dissociation map demonstrating boundaries between waves with an inter-
wave conduction velocity ≥19 cm/s (grey boxes : collision) or <19 cm/s
(black boxes , conduction block). Right panel : example of the spatial
distribution of epicardial breakthroughs (EB) during 8 s of AF at the right
atrial free wall. Each asterisk indicates a breakthrough site, its size being
proportional to the number of EBs occurring at that site. EBs are widely
distributed over the entire epicardial surface and occurred virtually every-
where. Lower right panel: schematic presentation of a pattern of EB as a
result of transmural dissociation in conduction. For simplicity, transmural
dissociation is represented by two planes only. In this example, the endo-
cardial layer is activated by a single fibrillation wave propagating from left
to right. In the middle, this endocardial wave is propagating transmurally
through a junction site with the epicardial layer. Assuming a transmural
conduction time of 10 ms, the breakthrough of the transmurally propagat-
ing wave appeared at t=25 ms at the epicardial surface (asterisk). Depend-
ing on the spatial distribution of electrophysiological properties such as
strength of depolarisation, excitability, electric coupling, and source-sink
relations, the spread of activation from this site of EB may vary [28, 29]
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unipolar, epicardial, AF electrograms recorded from the mid-
dle of the right atrial free wall during induced AF (upper
panel) and long-standing persistent AF (lower panel).
In both patients, there is a considerable beat-to-beat
variability in the morphology of the fibrillation poten-
tials that is more pronounced in the patient with long-
standing persistent AF. Fibrillation potentials obtained
from the latter patient are often prolonged and contain
multiple deflections (so-called fractionated potentials).
Mapping of AF is particularly challenging as these
complex recordings hamper a correct determination of the
local activation times. The hallmark of AF is a continuous
beat-to-beat change in the pattern of activation (Fig. 4) and
electrogram morphology. Thus, mapping of AF is very
complex.
QUASAR (QUest for the Arrhythmogenic Substrate
of Atrial fibR illation)
In recent studies, Allessie et al. introduced a novel high-
resolution mapping approach (‘wave mapping’) to compare
electrophysiological properties of fibrillation waves during
induced atrial fibrillation in patients with normal atria (phys-
iological AF) and during persistent AF in patients with val-
vular heart disease (pathological AF). This wave-mapping
technique allows visualisation of individual fibrillation waves
and quantification of the fibrillatory process. Epicardial wave
maps of the right atrial free wall, left atrium and the PV region
were constructed during persistent AF and compared with
epicardial maps of the right atrial free wall obtained during
induced AF. By applying this technique we were able to
differentiate physiological from pathological AF and demon-
strated that electrical dissociation of atrial muscle bundles
(Fig. 5: left panel) and epicardial breakthrough of fibrillation
waves (Fig. 5: right panel) play a key role in development of
the substrate of persistent AF [28, 29].
Hypothetically, multisite high-resolution atrial mapping
can be used to localise sources generating AF in patients with
trigger-driven AF and to identify areas perpetuating AF in
patients with substrate mediated-AF. Due to the large variety
of disorders associated with AF, it is feasible to assume that
there are inter-individual differences in the mechanisms un-
derlying AF and multisite high-resolution mapping of the
entire atria is therefore mandatory. In an attempt to diagnose
the substrate of AF in individual patients, we initiated the
QUASAR study (QUest for the Arrhythmogenic Substrate
of Atrial FibRillation) at the Erasmus Medical Center in
Rotterdam. In this project, we are developing a real-time,
high-resolution, multisite epicardial mapping technique of
the entire atria as a novel diagnostic tool. For this purpose,
we are performing epicardial mapping studies in a large num-
ber of patients undergoing cardiac surgery with a variety of
underlying structural heart diseases and different types of AF.
This new mapping technique (Fig. 6) can be used not only to
gain insights into the arrhythmogenic substrate of AF, but also
to develop novel therapies or to improve existing treatment
modalities.
Signals Activation ConductionVoltages
Fig. 6 Quest for the arrhythmogenic substrate of atrial fibrillation. An
epicardial, high resolution, multi-site mapping approach is used for
identification of the arrhythmogenic substrate in patients with AF. High
resolution mapping arrays (inter-electrode distances 1–2mm) are used for
epicardial mapping of the atria. Unipolar atrial potentials are used for
construction of activation, voltage and conduction block maps
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